QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Transforming Modern Cardiac Diagnostics
Zenosense (OTC: ZENO), through the development of MIDS Cardiac™, seeks to provide a technology that delivers laboratory-level accuracy at the point of care. An article discussing the company’s recent success reads: “A successful development of MIDS Cardiac is just the first step in the development of a wider technology platform that could be adapted to a wide range of point of care immunoassay tests, based on the same concepts of speed, accuracy, ease of use and cost-effectiveness. Zenosense and MIDS Medical Limited are planning to use the platform to develop a multi-capability, highly sensitive point of care device that could…